Phillip Lieberman, MD
Allergy & Immunology · Memphis, TNNPI 1629009717
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,719 of the $130,581 with a category attached, or 65.6%. 25 manufacturers reported payments, led by Sanofi at 48.4% of the total. Reporting peaked in 2019 at $82,476 and has fallen 99.9% since, to $55 in 2024. Among allergy & immunology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $640.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$63K
- Bayer$18K
- Regeneron Healthcare Solutions, Inc.$16K
- Shire North American Group Inc$6K
- Sanofi US Services Inc.$4K
- Pharming Healthcare, Inc.$4K
- plus $19K from 19 others
Across 2 payments — averaging $937.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
- Novo Nordisk AS$750
What the payments were for
- Consulting fees$30,55723%
- Speaking & faculty fees$85,71966%
- Travel & lodging$10,8638%
- Food & beverage$3,4433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 63 | $63,237 |
| Bayer | 9 | $17,624 |
| Regeneron Healthcare Solutions, Inc. | 25 | $16,462 |
| Shire North American Group Inc | 6 | $5,537 |
| Sanofi US Services Inc. | 4 | $4,382 |
| Pharming Healthcare, Inc. | 8 | $4,335 |
| Boehringer Ingelheim | 6 | $3,850 |
| Biocryst Pharmaceuticals, Inc. | 1 | $2,750 |
| Teva Pharmaceuticals USA, Inc. | 4 | $2,494 |
| AbbVie | 4 | $1,800 |
| Mylan Inc. | 1 | $1,452 |
| Biocryst US Sales Co., LLC | 2 | $1,395 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,238 |
| Hikma Pharmaceuticals USA | 1 | $1,000 |
| Kaleo, Inc. | 2 | $900 |
| Mylan Pharmaceuticals Inc. | 1 | $675 |
| Eagle Pharmaceuticals, Inc. | 1 | $400 |
| GSK | 22 | $321 |
| Genentech USA, Inc. | 14 | $220 |
| Novartis | 14 | $204 |
| CSL Behring | 6 | $166 |
| Optinose US, Inc. | 3 | $58 |
| Sunovion Pharmaceuticals Inc. | 4 | $50 |
| Pfizer | 1 | $19 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$130,581 in reported general payments places this provider in the 95th percentile of 79 allergy & immunology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 27 | $1,380,874 |
| IcatibantIcatibant Acetate | 13 | $242,380 |
| Dupixent SyringeDupilumab | 46 | $184,988 |
| Dupixent PenDupilumab | 45 | $183,866 |
| HyqviaIgg/Hyaluronidase,recombinant | 11 | $92,908 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $88,029 |
| XolairOmalizumab | 15 | $80,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $75,571 |
| NucalaMepolizumab | 11 | $47,028 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $34,772 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $18,762 |
| Arnuity ElliptaFluticasone Furoate | 37 | $15,528 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $12,455 |
| Epinephrine | 31 | $6,397 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $5,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Hyqvia | $1,238 | $1,473,78238 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $321 | $172,899176 claims |
| CSL BehringHizentra | $166 | $88,02912 claims |
| Hikma Pharmaceuticals USAEpinephrine | $1,000 | $6,39731 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $2,494 | $5,30013 claims |
| Mylan Inc.Wixela Inhub | $1,452 | $4,81130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Memphis
- Reena PatelMemphis$101K
- Jay LiebermanMemphis$81K
- Amy RagsdaleMemphis$8K
- Venusa PhomakayMemphis$6K
- Phuong leMemphis$3K
- Nicholas KolinskyKnoxville$472K
- Tidence PrinceMaryville$269K
- Tammy Heinly McCulleyGermantown$165K
- John FahrenholzNashville$124K
- Marc CromieChattanooga$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.